Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 69

Sort by

Sort Order Select

Journal Articles

Preliminary safety and efficacy of myeloablative orca-q with tacrolimus or without graft-versus-host disease prophylaxis for treatment of advanced hematologic malignancies

Samer Srour, Mehrdad Abedi, Amandeep Salhotra, Edmund Waller, Hannah Choe, Anna Pavlova, Tamara Zharkevich, Scott Killian, J. Scott McClellan, Nate Fernhoff, Robert Lowsky

Blood (2025) 146 (Supplement 1): 932.

https://doi.org/10.1182/blood-2025-932

Published: 2025

Journal Articles

The feasibility of collecting social determinants of health in the national multi-center GRASP sickle cell gene therapy trial

Colleen Kelly, Morgan Paul, Wendy London, Rahela Aziz-Bose, Puja Umaretiya, Erica Esrick, Victoria Coleman-Cowger, Gary Schiller, Mehrdad Abedi, Joseph Antin, Mary Horowitz, Neena Kapoor, Edmund Waller, Sonali Chaudhury, Mary Eapen, Mark Walters, David Williams, Kira Bona

Blood (2025) 146 (Supplement 1): 6224.

https://doi.org/10.1182/blood-2025-6224

Published: 2025

Journal Articles

Ibrutinib plus blinatumomab in Relapsed/Refractory B-cell acute lymphoblastic leukemia: Results of A phase 2 study

Brian Jonas, Mehrdad Abedi, Aaron Rosenberg, Naseem Esteghamat, Rasmus Hoeg, Lihong Qi, Eric Tam, Joseph Tuscano, George Yaghmour

Blood (2025) 146 (Supplement 1): 3356.

https://doi.org/10.1182/blood-2025-3356

Published: 2025

Journal Articles

First 20-patient safety and efficacy data from nexicart-2, the first u.S. trial of CAR-T in R/R light chain (AL) amyloidosis, nxc-201

Heather Landau, Shahzad Raza, Aaron Rosenberg, Jeffrey Zonder, Raymond Comenzo, Vaishali Sanchorawala, Michaela Liedtke, Amandeep Godara, Michael Rosenzweig, Charlotte Hughes, Eugene Brailovski, Mehrdad Abedi, Sham Mailankody, Jae Park, David Marks, Sridevi Rajeeve, Jennifer Liu

Blood (2025) 146 (Supplement 1): 696.

https://doi.org/10.1182/blood-2025-696

Published: 2025

Journal Articles

Chimeric antigen receptor (CAR) T-cell persistence at month 3 predicts clinical outcomes in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with obecabtagene autoleucel (obe-cel)

Claire Roddie, Jae Park, Eleni Tholouli, Karamjeet Sandhu, Paul Shaughnessy, Pere Barba, Manuel Guerreiro, Deborah Yallop, Aaron Logan, Mehrdad Abedi, Pierre Lao-Sirieix, Ping Wang, Wolfram Brugger, Bijal Shah, Anthony Hunter, Daniel Deangelo, Elias Jabbour

Blood (2025) 146 (Supplement 1): 5118.

https://doi.org/10.1182/blood-2025-5118

Published: 2025

Journal Articles

Efficacy and safety of loncastuximab tesirine and rituximab (Lonca-R) followed by dose-adjusted rituximab with etoposide, doxorubicin, cyclophosphamide, vincristine and prednisone (DA-R-EPOCH) in previously untreated high-risk diffuse large B-cell lymphoma (DLBCL): Preliminary results from a University of California Malignancy Consortium (UCHMC) Phase II trial, UCDCC#303.

Jacqueline Hsieh-Wong, Naseem Esteghamat, Rasmus Hoeg, Mehrdad Abedi, Sheila Firoozan, Aaron Rosenberg, Ashley Trane, Aneeqa Zafar, Shuai Chen, Siyao Li, Matthew Wieduwilt, Lloyd Damon, Benjamin Heyman, Haifaa Abdulhaq, Elizabeth Brem, Deepa Jeyakumar, Gary Schiller, Joseph Tuscano

Blood (2025) 146 (Supplement 1): 1966.

https://doi.org/10.1182/blood-2025-1966

Published: 2025

Journal Articles

Dose intensive regimen of CK0804 tregs in myelofibrosis

Lucia Masarova, Mehrdad Abedi, Naveen Pemmaraju, Prithviraj Bose, Tapan Kadia, Jo Ishizawa, Guillermo Montalban-Bravo, Tara Sadeghi, Simrit Parmar, Hagop Kantarjian

Blood (2025) 146 (Supplement 1): 5602.

https://doi.org/10.1182/blood-2025-5602

Published: 2025

Journal Articles

Highly efficient collection and manufacture of autologous HSC gene therapy cell product for patients with sickle cell disease using a lentiviral vector containing a shmir targeting BCL11a

Blood (2025) 146 (Supplement 1): 6094.

https://doi.org/10.1182/blood-2025-6094

Published: 2025

Journal Articles

Mechanistic basis of the acute safety profile of rese-cel, an autologous CD19-CAR T, in patients with autoimmune disease treated in four ongoing phase 1/2 clinical trials

Blood (2025) 146 (Supplement 1): 2336.

https://doi.org/10.1182/blood-2025-2336

Published: 2025

Journal Articles

A Phase I Study of CD19 CAR T-Cells with Escalating Doses of Lymphodepletion with or without Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Naseem S. Esteghamat, Joseph M Tuscano, Brian A. Jonas, Aaron S. Rosenberg, Rasmus T. Hoeg, Francisco Andres Socola, Brian Fury, Jordan Pavlic, Geralyn Annett, Jan A. Nolta, Mehrdad Abedi

Blood (2024) 144 (Supplement 1): 2085.

https://doi.org/10.1182/blood-2024-206680

Published: 2024

Journal Articles

Preliminary Safety and Efficacy of Myeloablative Orca-Q with No GvHD Prophylaxis for Treatment of Advanced Hematologic Malignancies

Mehrdad Abedi, Samer A. Srour, Amandeep Salhotra, Rasmus T. Hoeg, Edmund K. Waller, Hannah Choe, Anna Pavlova, Tamara Zharkevich, J. Scott McClellan, Nathaniel B. Fernhoff, Everett H. Meyer, Robert Lowsky

Blood (2024) 144 (Supplement 1): 382.

https://doi.org/10.1182/blood-2024-204256

Published: 2024

Journal Articles

Updated Results of a Phase I Study of Uproleselan Combined with Azacitidine and Venetoclax for the Treatment of Older or Unfit Patients with Treatment Naïve Acute Myeloid Leukemia

Brian A. Jonas, Zarir E. Karanjawala, Laura Molnar, Ashley Linh Dang-Chu, Mehrdad Abedi, Naseem S. Esteghamat, Aaron S. Rosenberg, Francisco Andres Socola, Lihong Qi, Joseph M. Tuscano

Blood (2024) 144 (Supplement 1): 1503.

https://doi.org/10.1182/blood-2024-212328

Published: 2024

Journal Articles

Risk Factors Associated with Sub-Optimal Outcomes Following Obecabtagene autoleucel (obe-cel) for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): What We Have Learned from the FELIX Trial

Claire Roddie, Jae H. Park, Paul Shaughnessy, Aaron C. Logan, Karamjeet S Sandhu, Mehrdad Abedi, Bijal D Shah, Michael R Bishop, Daniel J. DeAngelo, Wolfram Brugger, Martin A Pule, Justin Shang, Elias Jabbour

Blood (2024) 144 (Supplement 1): 4845.

https://doi.org/10.1182/blood-2024-208028

Published: 2024

Journal Articles

Healthcare Resource Utilization and Costs Associated with Managing CRS and ICANS in Patients with Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia Receiving Obecabtagene autoleucel (obe-cel)

Bijal D Shah, Jeremy Pantin, Karamjeet S Sandhu, Elias Jabbour, Jae H. Park, Paul Shaughnessy, Mehrdad Abedi, Michael R Bishop, Daniel J. DeAngelo, Wolfram Brugger, Martin Brown, Dilip Patel, Claire Roddie, Aaron C. Logan

Blood (2024) 144 (Supplement 1): 4837.

https://doi.org/10.1182/blood-2024-205694

Published: 2024

Journal Articles

Optimizing CAR-T Cell Therapy: Reducing Manufacturing Time and Examining T Cell Memory Phenotypes in B Cell Lymphoma

Jordan Pavlic, Brian Fury, Jen Mayo, Xayra Herrera, Sierra Jones, Dane Bergum, Geralyn Moser Annett, Jeannine Logan White, Naseem S. Esteghamat, Mehrdad Abedi, Jan A. Nolta

Blood (2024) 144 (Supplement 1): 7254.

https://doi.org/10.1182/blood-2024-204047

Published: 2024

Journal Articles

A Phase II Study of Brentuximab Vedotin and Bendamustine for Relapsed/Refractory Follicular Lymphoma

Guneet Kaleka, Benjamin Moskoff, Aneeqa Zafar, Naseem S. Esteghamat, Mehrdad Abedi, Francisco Andres Socola, Rasmus T. Hoeg, Joseph M Tuscano

Blood (2024) 144 (Supplement 1): 6318.

https://doi.org/10.1182/blood-2024-210372

Published: 2024

Journal Articles

A Phase I Trial of CC-486, Lenalidomide, Obinutuzumab in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Gabriel Marquez-Arreguin, Tamer Othman, Naseem S. Esteghamat, Mehrdad Abedi, Francisco Andres Socola, Joseph M Tuscano

Blood (2024) 144 (Supplement 1): 6317.

https://doi.org/10.1182/blood-2024-209452

Published: 2024

Journal Articles

Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) in the Open-Label, Multi-Center, Global, Single-Arm, Phase Ib/II FELIX Study: The Impact of Bridging Therapies on CAR T-Cell Expansion and Persistence

Jae H. Park, Elias Jabbour, Paul Shaughnessy, Aaron C. Logan, Karamjeet S Sandhu, Mehrdad Abedi, Bijal D Shah, Michael R Bishop, Daniel J. DeAngelo, Pierre Lao-Sirieix, Wolfram Brugger, Martin A Pule, Justin Shang, Claire Roddie

Blood (2024) 144 (Supplement 1): 3458.

https://doi.org/10.1182/blood-2024-201514

Published: 2024

Journal Articles

Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Deep Molecular Remission May Predict Better Outcomes

Elias Jabbour, Jae H. Park, Paul Shaughnessy, Aaron C. Logan, Karamjeet S Sandhu, Mehrdad Abedi, Bijal D Shah, Michael R Bishop, Daniel J. DeAngelo, Pierre Lao-Sirieix, Wolfram Brugger, Martin A Pule, Yiyun Zhang, Claire Roddie

Blood (2024) 144 (Supplement 1): 963.

https://doi.org/10.1182/blood-2024-194508

Published: 2024

Journal Articles

Observational Comparison of Overall Survival between Phase 1b Orca-T and Registry-Based Post-Transplant Cyclophosphamide Patients

Blood (2024) 144 (Supplement 1): 694.

https://doi.org/10.1182/blood-2024-205917

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Preliminary safety and efficacy of myeloablative orca-q with tacrolimus or without graft-versus-host disease prophylaxis for treatment of advanced hematologic malignancies

The feasibility of collecting social determinants of health in the national multi-center GRASP sickle cell gene therapy trial

Ibrutinib plus blinatumomab in Relapsed/Refractory B-cell acute lymphoblastic leukemia: Results of A phase 2 study

First 20-patient safety and efficacy data from nexicart-2, the first u.S. trial of CAR-T in R/R light chain (AL) amyloidosis, nxc-201

Chimeric antigen receptor (CAR) T-cell persistence at month 3 predicts clinical outcomes in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with obecabtagene autoleucel (obe-cel)

Dose intensive regimen of CK0804 tregs in myelofibrosis

Highly efficient collection and manufacture of autologous HSC gene therapy cell product for patients with sickle cell disease using a lentiviral vector containing a shmir targeting BCL11a

Mechanistic basis of the acute safety profile of rese-cel, an autologous CD19-CAR T, in patients with autoimmune disease treated in four ongoing phase 1/2 clinical trials

A Phase I Study of CD19 CAR T-Cells with Escalating Doses of Lymphodepletion with or without Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Preliminary Safety and Efficacy of Myeloablative Orca-Q with No GvHD Prophylaxis for Treatment of Advanced Hematologic Malignancies

Updated Results of a Phase I Study of Uproleselan Combined with Azacitidine and Venetoclax for the Treatment of Older or Unfit Patients with Treatment Naïve Acute Myeloid Leukemia

Risk Factors Associated with Sub-Optimal Outcomes Following Obecabtagene autoleucel (obe-cel) for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): What We Have Learned from the FELIX Trial

Healthcare Resource Utilization and Costs Associated with Managing CRS and ICANS in Patients with Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia Receiving Obecabtagene autoleucel (obe-cel)

Optimizing CAR-T Cell Therapy: Reducing Manufacturing Time and Examining T Cell Memory Phenotypes in B Cell Lymphoma

A Phase II Study of Brentuximab Vedotin and Bendamustine for Relapsed/Refractory Follicular Lymphoma

A Phase I Trial of CC-486, Lenalidomide, Obinutuzumab in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) in the Open-Label, Multi-Center, Global, Single-Arm, Phase Ib/II FELIX Study: The Impact of Bridging Therapies on CAR T-Cell Expansion and Persistence

Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Deep Molecular Remission May Predict Better Outcomes

Observational Comparison of Overall Survival between Phase 1b Orca-T and Registry-Based Post-Transplant Cyclophosphamide Patients

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only